Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 6/20 | 0.96 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.96 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.96 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.96 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.96 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.96 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.96 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.96 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.96 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.96 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.73 |
| ▸ | HTR1A known ✓ | P08908 | 7/20 | 0.70 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.63 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.63 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29397565 | 1.00 | LMNA (1.00) | LMNAMAPTHTR3ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL246416 | 1.00 | LMNA (1.00) | LMNAMAPTHTR3ADRD2DRD3 | |
| SCHEMBL6366499 | 0.98 | HTR3A (1.00) | LMNAMAPTHTR3ADRD2DRD3 | |
| SCHEMBL29396943 | 0.98 | HTR3A (1.00) | LMNAMAPTHTR3ADRD2DRD3 | |
| SCHEMBL379 | 0.98 | HTR3A (1.00) | LMNAMAPTHTR3ADRD2DRD3 | |
| Piperazine SCHEMBL28843777 | 0.96 | HTR3A (0.96) | LMNAMAPTHTR3ADRD2DRD3 | |
| Bromide SCHEMBL27797305 | 0.96 | HTR3A (0.96) | LMNAMAPTHTR3ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL9069817 | 0.95 | HTR3A (0.93) | LMNAMAPTHTR3ADRD2DRD3 | |
| Iodide SCHEMBL27505006 | 0.95 | HTR3A (0.93) | LMNAMAPTHTR3ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL253494 | 0.94 | LMNA (0.88) | LMNAMAPTHTR3ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103189373-B | The Triazolopyridine replaced | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-06 | — | — | CN | disclosed |
| CN-105408332-A | Substituted triazolopyridines | Bayer Pharma AG | 2016-03-16 | — | — | CN | disclosed |
| CN-105246891-A | Novel compounds for the treatment of cancer | Bayer Pharma AG | 2016-01-13 | — | — | CN | disclosed |
| CN-103189373-A | Substituted triazolopyridines | BAYER IP GMBH | 2013-07-03 | — | — | CN | disclosed |
| CN-101326246-B | Mixture of sulfide dyes | CIBA SC HOLDING AG | 2012-09-05 | — | — | CN | disclosed |
| CN-100486973-C | Novel benzodioxoles | HOFFMANN LA ROCHE (CH) | 2009-05-13 | — | — | CN | disclosed |
| CN-101326246-A | Mixture of sulfide dyes | CIBA SC HOLDING AG (CH) | 2008-12-17 | — | — | CN | disclosed |
| CN-1671684-A | New benzodioxoles | HOFFMANN LA ROCHE (CH) | 2005-09-21 | — | — | CN | disclosed |
| EP-1020453-B1 | 6,7-ASYMMETRICALLY DISUBSTITUTED QUINOXALINECARBOXYLIC ACID DERIVATIVES, ADDITION SALTS THEREOF, AND PROCESSES FOR THE PREPARATION OF BOTH | KYORIN SEIYAKU KK (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6348461-B1 | CENTRAL NERVOUS SYSTEM ANTAGONIST WITH HETEROCYCLIC SUBSTITUENTS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| CN-1139431-A | Heterocyclic compounds for the treatment of central nervous system and cardiovascular diseases | PHARMACIA & UPJOHN CO LLC (US) | 1997-01-01 | — | — | CN | disclosed |
| CN-1132508-A | Piperazine derivatives | REORDATI IND CHIMICA E FARMACE (CH) | 1996-10-02 | — | — | CN | disclosed |
| EP-0711288-A1 | PIPERAZINE DERIVATIVES AS ALPHA 1A-ADRENERGIC RECEPTOR ANTAGONISTS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 1996-05-15 | — | — | EP | disclosed |
| US-5474994-A | Treating hypertension, urethral and lower urinary tract contractions | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-12-12 | — | — | US | disclosed |
| WO-1995004049-A1 | PIPERAZINE DERIVATIVES AS α1A-ADRENERGIC RECEPTOR ANTAGONISTS | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-02-09 | — | — | WO | disclosed |
| US-4465683-A | TRIAZOLOPYRIDINONES | MEAD JOHNSON & COMPANY (US) | 1984-08-14 | — | — | US | disclosed |
| EP-0025603-B1 | TRIAZOLO (4,3-A)PYRIDIN-3(2H)-ONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Bristol-Myers Company (US) | 1983-11-02 | — | — | EP | disclosed |
| EP-0025603-A1 | Triazolo (4,3-a)pyridin-3(2H)-ones, process for their preparation and pharmaceutical compositions containing them | Bristol-Myers Company (US) | 1981-03-25 | — | — | EP | disclosed |
| US-4191765-A | 1-Aryloxy-2-hydroxy-3-aminopropanes | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-03-04 | — | — | US | disclosed |
| US-3948898-A | HYPOTENSIVES, SEDATIVES, ANTIARRHYTHMICS, BRADYCARDIACS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-04-06 | — | — | US | disclosed |